O
Olubukola M. Abiona
Researcher at National Institutes of Health
Publications - 26
Citations - 10874
Olubukola M. Abiona is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antibody & Neutralizing antibody. The author has an hindex of 15, co-authored 25 publications receiving 6970 citations.
Papers
More filters
Journal ArticleDOI
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Journal ArticleDOI
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Kizzmekia S. Corbett,Darin K. Edwards,Sarah R. Leist,Olubukola M. Abiona,Seyhan Boyoglu-Barnum,Rebecca A. Gillespie,Sunny Himansu,Alexandra Schäfer,Cynthia T. Ziwawo,Anthony T. DiPiazza,Kenneth H. Dinnon,Sayda Elbashir,Christine A. Shaw,Angela Woods,Ethan J. Fritch,David R. Martinez,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Geoffrey B. Hutchinson,Kai Wu,Carole Henry,Kapil Bahl,Dario Garcia-Dominguez,Ling Zhi Ma,Isabella Renzi,Wing Pui Kong,Stephen D. Schmidt,Lingshu Wang,Yi Zhang,Emily Phung,Emily Phung,Lauren A. Chang,Rebecca J. Loomis,Nedim Emil Altaras,Elisabeth Narayanan,Mihir Metkar,Vlad Presnyak,Cuiping Liu,Mark K. Louder,Wei Shi,Kwanyee Leung,Eun Sung Yang,Ande West,Kendra Gully,Laura J. Stevens,Nianshuang Wang,Daniel Wrapp,Nicole A. Doria-Rose,Guillaume Stewart-Jones,Hamilton Bennett,Gabriela S. Alvarado,Martha Nason,Tracy J. Ruckwardt,Jason S. McLellan,Mark R. Denison,James D. Chappell,Ian N. Moore,Kaitlyn M. Morabito,John R. Mascola,Ralph S. Baric,Andrea Carfi,Barney S. Graham +62 more
TL;DR: In this article, an mRNA vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is proposed, which is used to control the CoVID-19 global pandemic.
Journal ArticleDOI
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Kizzmekia S. Corbett,Barbara J. Flynn,Kathryn E. Foulds,Joseph R. Francica,Seyhan Boyoglu-Barnum,Anne P. Werner,Britta Flach,Sarah O’Connell,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Hanne Leth Andersen,David R. Martinez,Amy T. Noe,Naomi Douek,Mitzi M. Donaldson,Nadesh N Nji,Gabriela S. Alvarado,Darin K. Edwards,Dillon R. Flebbe,Evan Lamb,Nicole A. Doria-Rose,Bob C. Lin,Mark K. Louder,Sijy O'Dell,Stephen D. Schmidt,Emily Phung,Lauren A. Chang,Christina Yap,John-Paul Todd,Laurent Pessaint,Alex Van Ry,Shanai Browne,Jack Greenhouse,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey-Ann Campbell,Anthony Cook,Alan Dodson,Katelyn Steingrebe,Wei Shi,Yi Zhang,Olubukola M. Abiona,Lingshu Wang,Amarendra Pegu,Eun Sung Yang,Kwanyee Leung,Tongqing Zhou,I-Ting Teng,Alicia T. Widge,Ingelise J. Gordon,Laura Novik,Rebecca A. Gillespie,Rebecca J. Loomis,Juan I. Moliva,Guillaume Stewart-Jones,Sunny Himansu,Wing-Pui Kong,Martha Nason,Kaitlyn M. Morabito,Tracy J. Ruckwardt,Julie E. Ledgerwood,Martin R. Gaudinski,Peter D. Kwong,John R. Mascola,Andrea Carfi,Mark G. Lewis,Ralph S. Baric,Adrian B. McDermott,Ian N. Moore,Nancy J. Sullivan,Mario Roederer,Robert A. Seder,Barney S. Graham +73 more
TL;DR: Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung.
Posted ContentDOI
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The atomic-resolution structure of 2019-nCoV S should enable rapid development and evaluation of medical countermeasure (MCM) development to address the ongoing public health crisis.
Journal ArticleDOI
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
Bryan Edward Jones,Patricia Brown-Augsburger,Kizzmekia S. Corbett,Kathryn Westendorf,Julian Davies,Thomas P. Cujec,Christopher M. Wiethoff,Jamie L. Blackbourne,Beverly A. Heinz,Denisa Foster,Richard E. Higgs,Deepa Balasubramaniam,Lingshu Wang,Yi Zhang,Eun Sung Yang,Roza Bidshahri,Lucas Kraft,Yuri Hwang,Stefanie Žentelis,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Samuel J. Hinshaw,Sean A. Tycho,Davide Pellacani,Ping Xiang,Krithika Muthuraman,Solmaz Sobhanifar,Marissa H. Piper,Franz J. Triana,Jorg Hendle,A. Pustilnik,Andrew C. Adams,Shawn J. Berens,Ralph S. Baric,David R. Martinez,Robert W. Cross,Thomas W. Geisbert,Viktoriya Borisevich,Olubukola M. Abiona,Hayley M. Belli,Maren de Vries,Adil Mohamed,Meike Dittmann,Marie I. Samanovic,Mark J. Mulligan,Jory A. Goldsmith,Ching-Lin Hsieh,Nicole V. Johnson,Daniel Wrapp,Jason S. McLellan,Bryan C. Barnhart,Barney S. Graham,John R. Mascola,Carl L. Hansen,Ester Falconer +56 more
TL;DR: A microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19) as discussed by the authors.